[go: up one dir, main page]

KR900003177A - 테트라시클릭계 우울증 치료제 - Google Patents

테트라시클릭계 우울증 치료제 Download PDF

Info

Publication number
KR900003177A
KR900003177A KR1019890012102A KR890012102A KR900003177A KR 900003177 A KR900003177 A KR 900003177A KR 1019890012102 A KR1019890012102 A KR 1019890012102A KR 890012102 A KR890012102 A KR 890012102A KR 900003177 A KR900003177 A KR 900003177A
Authority
KR
South Korea
Prior art keywords
general formula
compound
functional derivatives
alkyl
different substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019890012102A
Other languages
English (en)
Inventor
후베르투스 비린가 요하네스
Original Assignee
에이.쥐.제이.베르메렌.에프. 쥐. 엠. 헤르만스
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이.쥐.제이.베르메렌.에프. 쥐. 엠. 헤르만스, 악조 엔.브이. filed Critical 에이.쥐.제이.베르메렌.에프. 쥐. 엠. 헤르만스
Publication of KR900003177A publication Critical patent/KR900003177A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음

Description

테트라시클릭계 우울증 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(Ⅰ)의 테트라시클릭 화합물 및 그의 작용성 유도체:
    상기 식에서, R1은 1개 또는 2개의 동일하거나 다른 치환기 H, OH, 할로겐, C1-C4알킬 또는 C1-C4알콕시이고; R2는 R1과 동일한 정의를 갖는, 1개 또는 2개의 동일하거나 다른 치환기이며; R3과 R4는 시스 배위를 갖는 2개의 치환기로서, 그들 중 1개는 H이고 나머지 다른 1개는 OH이고; R5는 H 또는 C1-C4알킬이며; X는 0 또는 S이고; n은 0 또는 1이다.
  2. 제1항에 있어서, 하기 일반식(Ⅱ)를 갖는 화합물 및 그의 작용성 유도체.
    (식중, R1,R2,R5및 n은 제1항에서 정의한 바와 같다)
  3. 제1항에 있어서, 하기 일반식(Ⅲ)을 갖는 화합물 및 그의 작용성 유도체:
  4. 제1항에 있어서, 하기 일반식(Ⅳ)를 갖는 화합물 및 그의 작용성 유도체:
  5. 관련 화합물들의 제조방법과 유사한 방법으로 제조공정을 실시하는 것을 특징으로 하는 제1항에서 정의한 화합물의 합성방법.
  6. 활성성분이 제1항에서 정의한 물질들중 1종 이상으로 구성되는 것을 특징으로 하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890012102A 1988-08-26 1989-08-25 테트라시클릭계 우울증 치료제 Ceased KR900003177A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8802109 1988-08-26
NL88.02109 1988-08-26

Publications (1)

Publication Number Publication Date
KR900003177A true KR900003177A (ko) 1990-03-23

Family

ID=19852805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012102A Ceased KR900003177A (ko) 1988-08-26 1989-08-25 테트라시클릭계 우울증 치료제

Country Status (16)

Country Link
US (1) US4977158A (ko)
EP (1) EP0357126B1 (ko)
JP (1) JP2521157B2 (ko)
KR (1) KR900003177A (ko)
AT (1) ATE104981T1 (ko)
AU (1) AU618392B2 (ko)
CA (1) CA1325807C (ko)
DE (1) DE68914917T2 (ko)
DK (1) DK415789A (ko)
ES (1) ES2056194T3 (ko)
FI (1) FI91638C (ko)
IE (1) IE62754B1 (ko)
MX (1) MX9203809A (ko)
NZ (1) NZ230128A (ko)
PT (1) PT91555B (ko)
ZA (1) ZA895623B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160790T3 (es) * 1995-02-08 2001-11-16 Novartis Ag 10-aminoalifatil-dibenzo(b,f)oxepinas de accion antineurodegenerativa.
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
HRP20020305A8 (en) 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20020440B1 (en) 2002-05-21 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
HRP20030956A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
JP5245428B2 (ja) * 2007-07-06 2013-07-24 住友化学株式会社 トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233958A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (+)-beloxepin and methods for its synthesis and use
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
BRPI0908098A2 (pt) 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4271179A (en) * 1976-05-24 1981-06-02 Akzona Incorporated 1,2,3,3a,8,12b-Hexahydro-dibenzo[1,2;5,6]cyclohepta[3,4-C]pyrroles and pharmaceutical use thereof
US4271177A (en) * 1976-05-24 1981-06-02 Akzona Incorporated 2,3,3a,12b-Tetrahydro-1H-dibenzo[2,3;6,7]thiepino[4,5-c]pyrroles and pharmaceutical use thereof
US4158059A (en) * 1976-05-24 1979-06-12 Akzona Incorporated Tension reducing 2,3,4,4a,9,136-hexahydro-dibenz[1,2;5,6]cyclohepta[3,4-c]py
AU604726B2 (en) * 1986-06-26 1991-01-03 Kyowa Hakko Kogyo Co. Ltd. Antiarrhythmic agent

Also Published As

Publication number Publication date
JP2521157B2 (ja) 1996-07-31
PT91555A (pt) 1990-03-08
DK415789A (da) 1990-02-27
AU618392B2 (en) 1991-12-19
EP0357126B1 (en) 1994-04-27
EP0357126A1 (en) 1990-03-07
FI91638B (fi) 1994-04-15
NZ230128A (en) 1990-10-26
JPH02111776A (ja) 1990-04-24
AU4002289A (en) 1990-03-01
DK415789D0 (da) 1989-08-23
ZA895623B (en) 1990-05-30
DE68914917T2 (de) 1994-08-11
IE892363L (en) 1990-02-26
FI893901A0 (fi) 1989-08-18
IE62754B1 (en) 1995-02-22
US4977158A (en) 1990-12-11
PT91555B (pt) 1995-05-04
MX9203809A (es) 1992-07-01
FI893901L (fi) 1990-02-27
ES2056194T3 (es) 1994-10-01
CA1325807C (en) 1994-01-04
FI91638C (fi) 1994-07-25
DE68914917D1 (de) 1994-06-01
ATE104981T1 (de) 1994-05-15

Similar Documents

Publication Publication Date Title
KR880006206A (ko) 퀴나졸리논 유도체 및 이의 제조방법
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
CA2119853A1 (fr) Nouvelles pyridothiadiazines, leurs procedes de preparation, et les compositions pharmaceutiques qui les contiennent
KR900006296A (ko) 이미다졸린 유도체 및 그의 제조방법
ATE159250T1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR930002311A (ko) N-페닐티오우레아 유도체 및 그의 약학적 용도
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
KR890014536A (ko) 축합 퀴놀린계 화합물, 축합 아크리딘계 화합물 및 그의 제조방법과 그것을 함유하는 항암제 조성물
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR950010897A (ko) 신규의 화학적 보호제(chemopreventive agent) 및 그의 제조방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR890008121A (ko) 로다닌 유도체 및 약제학적 조성물
KR890012960A (ko) 결정성 β-락탐 용매화물
KR870010070A (ko) 모라노린 유도체의 제조법
KR920701232A (ko) 신규 9α-히드록시-3-옥소-4,24(25)-스티그마스타디엔-26-산 유도체, 이의 제조법 및 이를 함유하는 약학 조성물
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR890003718A (ko) N- 알킬벤젠 술포닐 카르바모일-5- 클로로이소티아졸 유도체 및 살미생물제
ATE111919T1 (de) Antibiotikum-derivat.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890825

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940811

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890825

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970920

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19970920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I